MedTrace Logo

DC Vaccine in Colorectal Cancer

NCT03730948 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-05-24

Study results available
· View outcomes & findings →

Summary

This is a pilot study to assess the safety and tolerability, as well as the immune response rate, of mDC3 vaccine in patients with colorectal cancer.

Conditions

Interventions

BIOLOGICAL

DC vaccine

DC vaccine for colorectal cancer

Sponsors & Collaborators

  • Parker Institute for Cancer Immunotherapy

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Kim Reiss-Binder, MD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-12
Primary Completion
2022-02-22
Completion
2022-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03730948 on ClinicalTrials.gov